Netupitant

Systematic (IUPAC) name
	2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide
Clinical data
Legal status	Approved;
Identifiers
PubChem	CID: 6451149
ChemSpider	4953629
Chemical data
Formula	C30H32F6N4O
Molecular mass	578.59 g/mol
	SMILES Cc1ccccc1c2cc(ncc2N(C)C(=O)C(C)(C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C ;
	InChI InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3 ; Key:WAXQNWCZJDTGBU-UHFFFAOYSA-N ;

Netupitant is an antiemitic drug. In the United States, the combination drug netupitant/palonosetron (Akynzeo) is approved by the Food and Drug Administration for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.^[1]

Mechanism of action

Netupitant is a selective NK1 receptor antagonist.^[2]

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.